FRTX — Fresh Tracks Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $5.59m
- -$5.28m
- $8.01m
- 25
- 65
- 76
- 56
Annual income statement for Fresh Tracks Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.92 | 1.82 | 0.404 | 6.94 | 8.01 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.1 | 22.8 | 40.2 | 28.5 | 14.4 |
| Operating Profit | -22.1 | -21 | -39.8 | -21.5 | -6.36 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.9 | -20.9 | -39.5 | -21.1 | -5.69 |
| Net Income After Taxes | -23.9 | -20.9 | -39.5 | -21.1 | -5.69 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.9 | -20.9 | -39.5 | -21.1 | -5.69 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.6 | -20.9 | -39.5 | -21.1 | -5.69 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -166 | -38.4 | -22.3 | -7.51 | -1.06 |